I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ACR 2025

We will be contributing to topics related to
-
03:30 PM
Duration 120mins Chicago, USA
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Edward M. Vital, Benni Vargas, Julie Rae, Tracey Wang, Jason Hackney, Cary M. Looney, William F. Pendergraft III, Liz Lightstone, Brad H. Rovin, Richard A. Furie, Harini Raghu
Duration 120mins Chicago, USA
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard A. Furie,Teresa Baczkowska, Amit Saxena, Imran Hassan, Bongin Yoo, Ben Lanza, Himanshi Sehgal, Frederic Boissard, Jay P. Garg, Thomas Schindler, Elsa Martins, William F. Pendergraft, Brad H. Rovin
Duration 120mins Chicago, USA
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard A. Furie, Ioannis Parodis, Rachel Jones, Liz Lightstone, Olivia Hwang, Amelia Au-Yeung, Imran Hassan, Huiyan (Ashley) Mao, William F. Pendergraft III, Jay P. Garg, Harini Raghu, Brad H. Rovin
Duration 120mins Chicago, USA
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients With Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad H. Rovin, Jay P. Garg, Richard A. Furie, Rachel Jones, Amit Saxena, Pasquale Esposito, Fedra Irazoque Palazuelos, Elsa Martins, Claire Petry, Nicolas Frey, Bongin Yoo, Imran Hassan, Thomas Schindler, Theodore A. Omachi, William F. Pendergraft, Mittermayer B. Santiago, Gustavo Aroca-Martínez, Ana Malvar
08:15 PM
Duration 15mins Chicago
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients with Lupus Nephritis: A Retrospective Cohort Study in the United States
Lisa Lindsay, Shu Wang, Huong Trinh, Yunru (Claire) Huang, William F. Pendergraft III, Brad H. Rovin
03:30 PM
Duration 120mins Chicago, USA
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad H. Rovin, William F. Pendergraft III, Liz Lightstone, Eric Daugas, Richard A. Furie, Theodore A. Omachi, Imran Hassan, Elsa Martins, Thomas Schindler, Jay P. Garg, Luis F. Quintana, Piotr Leszczyński, Ana Malvar
Duration 120mins Chicago, USA
Real-World Immunosuppressant Treatment Patterns In Lupus Nephritis: A Retrospective Claims Database Analysis In The United States
Anisha M. Patel, Alexandra Miller, Lisa Lindsay, Danny Sheinson, Zhiyu Xia, William F. Pendergraft III, Maria Dall'Era
03:30 PM
Duration 120mins Chicago, USA
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Brad H. Rovin, Elsa Martins, Cary D. Austin, Harini Raghu, Caleb Chan, Patrick S. Chang, Jay P. Garg, Valeria Alberton, Mittermayer B. Santiago, Gustavo Aroca-Martínez, Fedra I. Palazuelos, Teresa Baczkowska, José Alfaro, Jorge Ravelo-Hernández, Richard A. Furie, Luís F. Pinto, Eduardo H. Albiero, Christopher Larsen, Bongin Yoo, Jennifer Pulley, Andrew Thorley, Thomas Schindler, Theodore A. Omachi, William F. Pendergraft III, Ana Malvar
Coming soon